Chronic hepatitis C in HIV-infected patients: Low eligibility and applicability of therapy with pegylated interferon-α plus ribavirin [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 2, 2005, Pages 238-240

  Rauch, Andri ^a   Egger, Martin ^a   Reichen, Jürg ^a   Furrer, Hansjakob ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; CLINICAL EXAMINATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; DECISION MAKING; DEMOGRAPHY; DRUG EFFICACY; ERADICATION THERAPY; EVALUATION; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LETTER; LIVER BIOPSY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUPERINFECTION; SWITZERLAND;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; ELIGIBILITY DETERMINATION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN;

EID: 13244291638     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000148535.97081.72     Document Type: Letter

References (13)

1. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
2. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356:1800-1805.
3. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;33:240-247.
4. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology. 2002;36(Suppl):S1-S2.
5. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS. 2004;18:1-12.
6. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.
7. Perrone C, Carrat F, Bani-Sadr F, et al. Final results of ANRS HCO2-RIBAVIC: a randomized controlled trial of pegylated interferon-alfa-2b plus ribavirin vs interferon-alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients [abstract 2004. A3295]. Presented at: XV International AIDS Conference; 2004; Bangkok.
8. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351: 438-450.
9. Fleming CA, Craven DE, Thornton D, et al. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis. 2003;36:97-100.
10. Fultz SL, Justice AC, Butt AA, et al. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis. 2003;36:1039-1046.
11. Hall CS, Charlebois ED, Hahn JA, et al. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med. 2004;19:357-365.
12. Moreno L, Quereda C, Moreno A, et al. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS. 2004;18:67-73.
13. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS. 2003;17:1023-1028.